Risk of Diverticulitis in Rheumatoid Arthritis Patients Treated With IL-6 Inhibitors Versus JAK Inhibitors: A Real-World Propensity-Matched Study (ACG 2026) - Aug 29, 2026 - Abstract #P4830; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "Two mutually exclusive cohorts were defined: IL-6 inhibitor users (tocilizumab, sarilumab, siltuximab) without JAK inhibitor exposure, and JAK inhibitor users (tofacitinib, baricitinib, upadacitinib, filgotinib) without IL-6 exposure...Outcomes were assessed at 5 years, 10 years, and all follow-up after 1:1 propensity score matching for age, sex, diabetes, obesity, tobacco use, prior diverticular disease, alcohol-related disorders, NSAID, glucocorticoid, and methotrexate use... After matching, 10,459 patients remained per cohort, well-balanced (all standardized differences < =0.04). At 5 years, diverticulitis occurred in 160 IL-6 patients (1.6%) versus 146 JAK patients (1.4%): RR 1.092 (95% CI 0.874-1.365), p=0.436; HR 1.196 (0.955-1.497). At 10 years, 192 (1.9%) versus 172 (1.7%): RR 1.113 (0.907-1.365), p=0.304; HR 1.182 (0.962-1.453)."
Clinical • Real-world • Real-world evidence • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Rheumatoid Arthritis • Rheumatology
|
|
Yeshika Thapa MD 1; Toufic Dabit MD 2; Bsher Almaalouli MD 1; Kobina Essilfie-Quaye MD 3; Farah Haneyah MD 2; Jyoti Yadav MD 4; Tony Brar MD 5; Yaseen Perbtani DO 5
|